Supplementary Table 2.

Sensitivity Analysis by Excluding Each Study One at a Time

Study Excluded	Pooled HR or OR (95% CI)	Heterogeneity (I2) (%)
Famotidine and severe disease: analysis of studies reporting data as HR
Freedberg 2020	0.96 (0.27–3.44)	93
Mather 2020	0.91 (0.22–3.79)	91
Zhou 2020	0.48 (0.32–0.71)	0
PPI and severe disease: analysis of studies reporting data as OR
Cheung 2020	1.84 (1.27–2.64)	0
Lee 2020	1.79 (1.12–2.85)	0
Ramachandran 2020	1.62 (1.05–2.47)	0
Yeramaneni 2020	1.93 (1.26–2.95)	0